arrow
L

Louis Fehrenbacher

pennsylvania commonwealth system of higher education (pcshe)
H指数:78
被引数:5.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

来自NRG肿瘤学/NSABP B-42试验的乳腺癌指数和激素受体阳性乳腺癌中延长芳香化酶抑制剂治疗益处的预测

2024-02-204
OAAI
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer
2023-05-1512
OA
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) (March, 10.1007/s10549-021-06417-y, 2022)
2022-05-041
OA
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
2022-03-014
OA
Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42
2022-02-150
PRE
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
2022-02-031
OA
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

在曲妥珠单抗和卡培他滨的基础上加用特卡替尼或安慰剂治疗的人表皮生长因子受体2阳性转移性乳腺癌患者的生活质量保护 (HER2CLIMB试验)

2021-08-0111
OAAI
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
2021-05-2811
OAAI
Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
2020-02-157
PRE
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
2019-10-2123
OAAI
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

间质肿瘤浸润淋巴细胞在早期HER2-Positive乳腺癌NRG肿瘤学/NSABP B-31辅助试验中的应用

2019-03-1938
OAAI
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
2018-09-01100
OAAI
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Talazoparib在患有晚期乳腺癌和生殖系BRCA突变的患者中

2018-08-231.5K
OAAI